Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium animalis subsp. lactis CP-9
- Development stage
- Preclinical
- Lead developer
- Glac Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium animalis subsp. lactis CP-9 is a specific strain of probiotic bacteria that was originally isolated from human breast milk. It is developed by Glac Biotech and has received Generally Recognized as Safe (GRAS) status from the U.S. FDA, allowing for its use in a variety of food products, including infant formula. Clinical studies have investigated its use as an adjuvant to phototherapy for neonatal jaundice. The proposed mechanism for this indication is the inhibition of β-glucuronidase-producing E. coli, which reduces the enterohepatic circulation of bilirubin, thereby lowering serum bilirubin levels and shortening the required duration of phototherapy. Beyond neonatal health, the CP-9 strain has also been studied for other health benefits, including weight management, improvement of lipid metabolism, and immune support.
- Brand names
- Bioflag
- Other names
- Bifidobacterium animalis subsp. lactis strain CP-9Bifidobacterium lactis CP-9
02
Targets
GUSB (Beta-glucuronidase)
Beyond the preview
Go deeper on Bifidobacterium animalis subsp. lactis CP-9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium animalis subsp. lactis CP-9.